
CytomX hits $5M milestone with Regeneron on cancer drug collaboration using conditionally activated bispecifics
CytomX Therapeutics announced it reached a $5 million preclinical milestone in its collaboration with Regeneron to develop conditionally activated bispecific antibodies for cancer treatment. This partnership combines CytomX's PROBODY® technology with...



